294 related articles for article (PubMed ID: 12416895)
21. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
[TBL] [Abstract][Full Text] [Related]
22. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
23. Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation.
Salloum E; Tanoue LT; Wackers FJ; Zelterman D; Hu GL; Cooper DL
Cancer Invest; 1999; 17(3):171-80. PubMed ID: 10099655
[TBL] [Abstract][Full Text] [Related]
24. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
25. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.
Hunger SP; Link MP; Donaldson SS
J Clin Oncol; 1994 Oct; 12(10):2160-6. PubMed ID: 7523608
[TBL] [Abstract][Full Text] [Related]
26. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
[TBL] [Abstract][Full Text] [Related]
27. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
[TBL] [Abstract][Full Text] [Related]
29. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients.
Fermé C; Lepage E; Brice P; D'Agay MF; Fermand JP; Castaigne S; Frija J; Miot C; Marty M; Gisselbrecht C
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):397-405. PubMed ID: 7685749
[TBL] [Abstract][Full Text] [Related]
30. Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
Salvagno L; Sorarù M; Sotti G; Aversa S; Chiarion Sileni V; Mazzarotto R; Scarzello G; Bianco A; Pappagallo GL; Fiorentino MV
Ann Oncol; 1995 Feb; 6(2):173-9. PubMed ID: 7540419
[TBL] [Abstract][Full Text] [Related]
31. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
[TBL] [Abstract][Full Text] [Related]
32. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
[TBL] [Abstract][Full Text] [Related]
33. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
Loeffler M; Diehl V; Pfreundschuh M; Rühl U; Hasenclever D; Nisters-Backes H; Sieber M; Tesch H; Franklin J; Geilen W; Bartels H; Cartoni C; Dölken G; Enzian J; Fuchs R; Gassmann W; Gerhartz H; Hagen-Aukamp U; Hiller E; Hinkelbein H; Hinterberger W; Kirchner H; Koch P; Krüger B; Schwarze EW
J Clin Oncol; 1997 Jun; 15(6):2275-87. PubMed ID: 9196141
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
Wang WH; Li YX; Song YW; Jin J; Liu YP; Wang SL; Zhou LQ; Liu XF; Yu ZH; Han JZ
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):218-21. PubMed ID: 16875611
[TBL] [Abstract][Full Text] [Related]
35. Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage).
Zanini M; Viviani S; Santoro A; Soncini F; Bonfante V; Devizzi L; Villani F; Castellani MR; Negretti E; Zucali R
Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):813-9. PubMed ID: 7525516
[TBL] [Abstract][Full Text] [Related]
36. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
[TBL] [Abstract][Full Text] [Related]
37. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
38. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
39. Involved-field radiotherapy for advanced Hodgkin's lymphoma.
Aleman BM; Raemaekers JM; Tirelli U; Bortolus R; van 't Veer MB; Lybeert ML; Keuning JJ; Carde P; Girinsky T; van der Maazen RW; Tomsic R; Vovk M; van Hoof A; Demeestere G; Lugtenburg PJ; Thomas J; Schroyens W; De Boeck K; Baars JW; Kluin-Nelemans JC; Carrie C; Aoudjhane M; Bron D; Eghbali H; Smit WG; Meerwaldt JH; Hagenbeek A; Pinna A; Henry-Amar M;
N Engl J Med; 2003 Jun; 348(24):2396-406. PubMed ID: 12802025
[TBL] [Abstract][Full Text] [Related]
40. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Wilder RB; Schlembach PJ; Jones D; Chronowski GM; Ha CS; Younes A; Hagemeister FB; Barista I; Cabanillas F; Cox JD
Cancer; 2002 Mar; 94(6):1731-8. PubMed ID: 11920535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
